Literature DB >> 22584787

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

T Elter, R James, R Busch, D Winkler, M Ritgen, S Böttcher, C Kahl, W Gassmann, M Stauch, I Hasan, P Staib, K Fischer, A-M Fink, J Bahlo, A Bühler, H Döhner, C-M Wendtner, S Stilgenbauer, A Engert, M Hallek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22584787     DOI： 10.1038/leu.2012.129

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Authors:  Paula Cramer; Susanne Isfort; Jasmin Bahlo; Stephan Stilgenbauer; Hartmut Döhner; Manuela Bergmann; Martina Stauch; Michael Kneba; Elisabeth Lange; Petra Langerbeins; Natali Pflug; Gabor Kovacs; Valentin Goede; Anna-Maria Fink; Thomas Elter; Kirsten Fischer; Clemens-Martin Wendtner; Michael Hallek; Barbara Eichhorst
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

2.  Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Authors:  Marco Montillo; Alessandra Tedeschi; Gianluca Gaidano; Marta Coscia; Valeria Belsito Petrizzi; Ester Orlandi; Nicola Cascavilla; Paolo Ghia; Marina Motta; Andrea Gallamini; Anna Maria Frustaci; Davide Rossi; Lorenzo De Paoli; Michele Nichelatti; Enrica Morra; Massimo Massaia
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

Review 3.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

4.  Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.

Authors:  Jeremy L Warner; Jon E Arnason
Journal:  Ther Adv Hematol       Date:  2012-12

5.  Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Authors:  Clive S Zent; Ronald P Taylor; Margaret A Lindorfer; Paul V Beum; Betsy LaPlant; Wenting Wu; Timothy G Call; Deborah A Bowen; Michael J Conte; Lori A Frederick; Brian K Link; Sue E Blackwell; Suresh Veeramani; Nisar A Baig; David S Viswanatha; George J Weiner; Thomas E Witzig
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

Review 6.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 7.  What do we do with chronic lymphocytic leukemia with 17p deletion?

Authors:  L Sellner; S Denzinger; S Dietrich; H Glimm; O Merkel; P Dreger; T Zenz
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.